Cytek Biosciences, Inc.

Cytek Biosciences, Inc.

CTKBยทNASDAQ

$4.05

-3.3%
HealthcareMedical - Devices

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

At a Glance

Live Snapshot
Market Cap$523.03M
EPS-0.5200
P/E Ratio-7.79
Earnings Date08/05/2026
3Y-11.0%
5Y+110.0%
10Y+556.0%
3Y+28.0%
5Y-49.0%
10Y+7.0%
3Y-20.0%
5Y-2232.0%
10Y-919.0%
ctkb

Cytek Biosciences, Inc. Funding & Solvency Profile

CTKB ยท NASDAQ
Cash & Cash Equivalents90.85M
Net Receivables72.13M
Inventory48.43M
Other Current Assets9.91M
Total Current Assets392 M
Property, Plant & Equipment29.32M
Goodwill & Intangible Assets33.52M
Long-Term Investments0.00
Other Non-Current Assets6.70M
Total Non-Current Assets36 M
Total Assets
461.54M

Financial Health Analysis

Current Ratio

5.04x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.35x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

314 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

85% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Cytek Biosciences, Inc. Balance Sheet

CTKB โ€ข NASDAQ

Cytek Biosciences, Inc. Balance SheetDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
ASSETS
CURRENT ASSETS
90.9M
98.7M
167.3M
296.6M
364.6M
165.2M
30.1M
170.7M
179.1M
95.1M
44.5M
0.0
0.0
0.0
261.5M
277.9M
262.4M
341.1M
364.6M
165.2M
30.1M
72.1M
60.6M
56.1M
50.9M
29.6M
18.1M
17.7M
62.5M
60.6M
55.9M
48.9M
29.8M
17M
17.1M
9.6M
0.0
192K
2M
-127K
1.1M
597K
48.4M
43.9M
60.9M
48.2M
32.2M
23M
18.4M
0.0
12.1M
10.1M
7.1M
4.6M
936K
1M
9.9M
2M
2.6M
6.7M
708K
1.3M
419K
392M
396.4M
392.1M
454M
431.7M
208.6M
67.8M
NON-CURRENT ASSETS
29.3M
28.1M
29.3M
27.6M
5.9M
2.1M
1M
16.7M
16.7M
16.2M
10.1M
10.1M
476K
476K
16.8M
20.1M
23.1M
4.3M
4.7M
274K
263K
33.5M
36.8M
39.3M
14.5M
14.9M
750K
739K
0.0
1.6M
1.6M
0.0
0.0
0.0
0.0
0.0
33.4M
30.5M
20.5M
9.2M
7.4M
0.0
6.7M
3.2M
1.8M
3M
1.7M
1.1M
816K
69.5M
103.1M
102.4M
65.5M
31.6M
11.4M
2.6M
461.5M
499.5M
494.5M
519.5M
463.3M
220M
70.4M
LIABILITIES
CURRENT LIABILITIES
6.4M
9.1M
3M
6.5M
6.9M
4M
2.9M
6.4M
5.5M
3M
4.8M
3M
2.9M
2.3M
0.0
3.6M
0.0
1.7M
3.9M
1M
571K
0.0
21.7M
6.3M
7.2M
6.1M
3.5M
4.2M
11.7M
4.7M
565K
580K
0.0
2.8M
0.0
0.0
3.8M
2.4M
2.9M
0.0
0.0
0.0
0.0
3.6M
1.3M
1.7M
3.9M
1M
571K
28.5M
26.6M
22.7M
14.5M
8.1M
4.3M
3.5M
31.2M
1.9M
21.2M
17.3M
12M
12M
10.5M
77.8M
67.7M
56.2M
49M
33.2M
26.5M
21M
NON-CURRENT LIABILITIES
7.3M
1.1M
1.6M
2.3M
0.0
0.0
0.0
18.3M
16.1M
15.1M
13.1M
9.8M
3.5M
1.8M
9.1M
11.4M
18.9M
17.2M
14.9M
206M
89.2M
42M
36.1M
45.2M
44.9M
24.7M
209.5M
91M
14M
11.3M
11.9M
15.2M
0.0
0.0
0.0
119.8M
103.8M
101.4M
93.9M
57.9M
236M
112.1M
SHAREHOLDERS' EQUITY
129K
129K
131K
135K
126K
23K
21K
441.1M
430.8M
423.4M
442.9M
423.6M
6.5M
443K
-101.7M
-35.2M
-29.2M
-17M
-19.6M
-22.6M
-42M
2.2M
16K
-1.3M
-697K
897K
65K
-147K
341.7M
395.7M
393.1M
425.3M
405M
-16M
-41.7M
341.7M
395.7M
393.1M
425.5M
405.4M
-16M
-41.7M
0.0
0.0
0.0
251K
343K
0.0
0.0
SUMMARY
461.5M
499.5M
494.5M
519.5M
463.3M
220M
70.4M
170.7M
180.7M
96.7M
44.5M
0.0
0.0
0.0
33M
17M
14.1M
18.1M
0.0
2.8M
0.0
-57.8M
-81.7M
-153.2M
-278.5M
-364.6M
-162.5M
-30.1M
127,862,237
127,862,237
127,862,237
127,862,237
127,862,237
127,862,237
127,862,237

SEC Filings

CTKB - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

June 02, 2026
May 27, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 07, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 07, 2026
May 07, 2026
2026
DEF 14A

DEF 14A 2026

N/A

April 28, 2026
June 10, 2026
2026
10-K

10-K 2025 FY

FY

February 26, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 26, 2026
February 26, 2026
2026
8-K

8-K 2026

N/A

January 13, 2026
January 12, 2026
2026
10-Q

10-Q 2025 Q3

Q3

November 05, 2025
September 30, 2025
2025
8-K

8-K 2025

N/A

November 05, 2025
November 05, 2025
2025
8-K

8-K 2025

N/A

August 06, 2025
August 06, 2025
2025
Showing 1 to 10 of 70 filings